Cowen and Company reaffirmed their outperform rating on shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in a research report report published on Monday, The Fly reports. The firm currently has a $16.00 price objective on the stock, up from their previous price objective of $13.00.

Other equities analysts have also issued reports about the stock. Oppenheimer Holdings, Inc. raised shares of TherapeuticsMD from a market perform rating to an outperform rating and set a $10.00 price objective on the stock in a research report on Tuesday, July 11th. Cantor Fitzgerald reissued an overweight rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research report on Friday, July 21st. CIBC raised shares of TherapeuticsMD from a market perform rating to an outperform rating in a research report on Tuesday, July 11th. Noble Financial reissued a buy rating on shares of TherapeuticsMD in a research report on Friday, August 4th. Finally, Jefferies Group LLC reissued a buy rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research report on Friday, September 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $15.25.

Shares of TherapeuticsMD (NASDAQ TXMD) traded up $0.05 on Monday, reaching $5.66. 1,604,200 shares of the company traded hands, compared to its average volume of 4,070,000. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company’s revenue for the quarter was down 19.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) earnings per share. analysts forecast that TherapeuticsMD will post -0.39 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD, Inc. (TXMD) Earns Outperform Rating from Cowen and Company” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/10/therapeuticsmd-inc-txmd-earns-outperform-rating-from-cowen-and-company.html.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were acquired at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now directly owns 3,555 shares in the company, valued at $21,294.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 23.92% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of TXMD. JPMorgan Chase & Co. lifted its position in shares of TherapeuticsMD by 40.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after purchasing an additional 6,340,346 shares during the period. Bank of New York Mellon Corp increased its stake in shares of TherapeuticsMD by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock valued at $136,894,000 after acquiring an additional 2,985,846 shares in the last quarter. Stifel Financial Corp increased its stake in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after acquiring an additional 1,622,668 shares in the last quarter. Voya Investment Management LLC increased its stake in shares of TherapeuticsMD by 33.4% in the 2nd quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock valued at $15,595,000 after acquiring an additional 741,588 shares in the last quarter. Finally, State Street Corp increased its stake in shares of TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock valued at $23,647,000 after acquiring an additional 583,094 shares in the last quarter. Hedge funds and other institutional investors own 71.40% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

The Fly

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related stocks with our FREE daily email newsletter.